Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
7%
Atazanavir
5%
Cabotegravir
16%
Clinical Trial
23%
Disease
26%
Drug Resistant Tuberculosis
12%
Efavirenz
11%
Gamma Interferon
6%
HIV
100%
HIV Associated Dementia
7%
Human Immunodeficiency Virus 1
12%
Human Immunodeficiency Virus 1 Infection
8%
Human Immunodeficiency Virus Infection
12%
Infection
12%
Isoniazid
20%
Latent Tuberculosis
6%
Lung Tuberculosis
10%
Mixed Infection
5%
Multi-Drug-Resistant Tuberculosis
6%
Pharmacokinetics
14%
Prevalence
6%
Proteinase Inhibitor
8%
Rifampicin
11%
Rifapentine
17%
Rilpivirine
16%
RNA Directed DNA Polymerase Inhibitor
10%
Tuberculosis
18%
Tuberculostatic Agent
5%
Medicine and Dentistry
Antiretroviral Therapy
16%
Arm
5%
Cabotegravir
13%
Cell Count
5%
Clinical Trial
10%
Cross Sectional Study
5%
Diagnosis
6%
Disease
11%
Drug Resistant Tuberculosis
6%
Hepatitis C Virus
6%
Household
13%
Human Immunodeficiency Virus
63%
Human Immunodeficiency Virus 1
7%
Human Immunodeficiency Virus 1 Infection
9%
Human Immunodeficiency Virus Infection
11%
Infection
12%
Latent Tuberculosis
5%
Low and Middle Income Countries
6%
Multidrug Resistant Tuberculosis
6%
Pre-Exposure Prophylaxis
6%
Prevalence
7%
Prophylaxis
9%
Rifampicin
7%
Rilpivirine
11%
Tenofovir Alafenamide
6%
Tuberculosis
13%
Keyphrases
AIDS/HIV
12%
Antiretroviral Therapy
7%
CD4 Count
5%
Efavirenz
6%
HIV Infection
5%
HIV Patients
5%
HIV RNA
5%
Human Immunodeficiency Virus Type 1 (HIV-1)
16%
Long-acting Antiretrovirals
6%
People Living with HIV (PLHIV)
10%
Phase II Trial
5%
Rifapentine
9%
Rilpivirine
5%
Tuberculosis
7%
Virological Failure
6%